Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors

被引：0

作者：

Heymach, John ^{[1
]}

Yamamoto, Noboru ^{[2
]}

Opdam, Frans ^{[3
]}

Barve, Minal ^{[4
]}

Tu, Hai-Yan ^{[5
]}

Wu, Yi-Long ^{[5
]}

Schroeter, Lukas ^{[6
]}

Sadrolhefazi, Behbood ^{[7
]}

Serra, Josep ^{[8
]}

Yoh, Kiyotaka ^{[9
]}

Berz, David ^{[10
]}

机构：

[1] Univ Texas Houston, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA

[2] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[3] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands

[4] Mary Crowley Canc Res, Dallas, TX USA

[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China

[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[8] 8 Boehringer Ingelheim Espana SA, Barcelona, Spain

[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[10] Valkyrie Clin Trials, Los Angeles, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA01.01

引用

页码：E1 / E1

页数：1

共 50 条

[31] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Opdam, F.
Heymach, J.
Barve, M.
Gibson, N.
Sadrolhefazi, B.
Serra, J.
Yamamoto, N.
ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
[32] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations.
Heymach, John
Opdam, Frans
Barve, Minal A.
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yamamoto, Noboru
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations.
Heymach, John
Opdam, Frans
Barve, Minal
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yamamoto, Noboru
CANCER RESEARCH, 2022, 82 (12)
[34] A PHASE 1 STUDY OF MM-111; A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, COMBINED WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
Richards, D.
Braiteh, F.
Anthony, S.
Edenfield, W.
Hellerstedt, B.
Raju, R.
Conkling, P.
McDonagh, C.
Frye, S.
Moyo, V.
ANNALS OF ONCOLOGY, 2012, 23 : 170 - 170
[35] Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
McAndrew, Nicholas P.
Hu, Xichun
Zhang, Jian
Wang, Xiaojia
Yu, Wenlei
Pan, Xiaomei
CANCER RESEARCH, 2023, 83 (05)
[36] A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
Cresti, N.
Jodrell, D.
Arkenau, T.
Forster, M.
Donaldson, K.
Posner, J.
Kawabata, I.
Plummer, R.
Spicer, J.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S160 - S161
[37] Lapatinib, a Dual HER1/HER2 Tyrosine Kinase Inhibitor, Augments Basal Cleavage of HER2 Extracellular Domain (ECD) to Inhibit HER2-Driven Cancer Cell Growth
Vazquez-Martin, Alejandro
Oliveras-Ferraros, Cristina
Cufi, Silvia
del Barco, Sonia
Martin-Castillo, Begona
Menendez, Javier A.
JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (01) : 52 - 57
[38] A phase Ⅰ study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
Pin Zhang
Lin Wang
Yueying Zhen
Zhihong Wang
Hesheng Zhang
Richard Jones
Binghe Xu
ChineseJournalofCancerResearch, 2024, 36 (01) : 46 - 54
[39] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
Sarina A. Piha-Paul
Analía Azaro
Hendrik Tobias Arkenau
Do-Youn Oh
Matthew D. Galsky
Sumanta Kumar Pal
Kensuke Hamada
Yaohua He
Ikuo Yamamiya
Karim A Benhadji
Antoine Hollebecque
Investigational New Drugs, 2021, 39 : 1324 - 1334
[40] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
Piha-Paul, Sarina A.
Azaro, Analia
Arkenau, Hendrik Tobias
Oh, Do-Youn
Galsky, Matthew D.
Pal, Sumanta Kumar
Hamada, Kensuke
He, Yaohua
Yamamiya, Ikuo
Benhadji, Karim A.
Hollebecque, Antoine
INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1324 - 1334

← 1 2 3 4 5 →